Report of a WHO informal consultation on animal models for evaluation of drugs and vaccines for HIV infection and AIDS. W.H.O., Geneva, 14-15 September 1989.
The use of animal models in the preclinical evaluation of anti-HIV drugs and vaccines was discussed at an informal consultation at World Health Organization headquarters in Geneva, 14-15 September 1989. The consultation was attended by six experts from four countries. HIV animal models, other lentivirus/animal models and oncornavirus/animal models were discussed, and their advantages and disadvantages were compared to hypothetical ideal HIV/animal models for preclinical evaluation of anti-HIV drugs and vaccines. The consultation concluded that infection of rhesus monkeys with the simian immunodeficiency virus (SIV) presently represents the best model system available since SIV closely resembles HIV in molecular architecture and pathogenicity. However, costs and availability of rhesus monkeys preclude widespread use for testing, and in many instances, other animal/retrovirus systems can be substituted. Schemes for the rational development of candidate anti-HIV drugs and vaccines were proposed. Recommendations were made to the World Health Organization, which include the use of appropriate small animal models prior to studies in non-human primates, restricting the use of chimpanzees to the final stages of vaccine testing after a prototype SIV vaccine has been shown to prevent infection, and gathering information on safety and efficacy in animal models prior to the initiation of phase I trials in humans.
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000818:Animals; D000998:Antiviral Agents; D004195:Disease Models, Animal; D006678:HIV / Q000187:drug effects*; D016086:Lentivirus / Q000187:drug effects; D016180:Lentivirus Infections; D012190:Retroviridae / Q000187:drug effects; D014765:Viral Vaccines
D000998:Antiviral Agents; D014765:Viral Vaccines